🔍

GKSL - Gujarat Kidney

📊 NSE: GKSL 📅 Last Updated: 11/13/2025 15:25

📢 Recent Corporate Announcements

GKSL Announces Resignation of Company Secretary and Compliance Officer Niki Paresh Tiwari

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 03 Mar 2026, 01:41 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges that Mrs. Niki Paresh Tiwari has resigned from her role as Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP). The resignation was tendered on March 2, 2026, as she intends to pursue career opportunities outside the organization. The company has accepted her resignation and fixed her official relieving date as March 27, 2026. GKSL has already initiated the process of shortlisting potential candidates to fill the vacancy within the timelines prescribed by SEBI regulations.

Mrs. Niki Paresh Tiwari resigned as Company Secretary and Compliance Officer effective March 2, 2026.
The official relieving date for the outgoing KMP has been set for March 27, 2026.
The resignation is attributed to the pursuit of better career opportunities outside the company.
The company is currently in the process of shortlisting candidates to ensure compliance with SEBI (LODR) Regulations regarding KMP appointments.

💡 This is a routine administrative change and does not impact the company's fundamentals. Investors should monitor for the announcement of a new appointment to ensure seamless regulatory compliance.

GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 14 Feb 2026, 11:57 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.

Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.
Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.
Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.
Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.
Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.

💡 Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.

GKSL Receives NCLT Approval for Voluntary Revision of Financials and Board Reports (FY22-FY24)

🟡 NEUTRAL ⭐ 5/10

REGULATORY 📅 14 Feb 2026, 09:21 PM

Gujarat Kidney and Super Speciality Limited (GKSL) has received NCLT approval to voluntarily revise its Board Reports and Financial Statements for three financial years (FY22, FY23, and FY24). The revisions primarily address clerical errors, such as incorrect board meeting dates and director appointment timelines. Crucially, the company is correcting a miscategorization in FY24 where a business transfer amount was wrongly labeled as a 'Loan to directors.' Management has confirmed that these revisions have no impact on the company's financial performance, operations, or other activities.

NCLT Ahmedabad approved the voluntary revision of Board Reports and Financial Statements for FY 2021-22, 2022-23, and 2023-24.
Correction of a miscategorized 'Loan to directors' in FY24 notes, which was actually related to a Business Transfer Agreement.
Rectification of clerical errors regarding the company's conversion date from Private to Public (corrected to 24/11/2023).
The company is directed to pay a nominal fee of ₹10,000 and file revised Form AOC-4 within 30 days.
Management and auditors state there is no quantifiable monetary impact on the company's financial or operational status.

💡 Investors should view this as a corrective governance measure to ensure regulatory accuracy; no immediate action is required as the financials remain fundamentally unchanged. Monitor the filing of the revised reports to confirm the 'Loan to directors' miscategorization is officially resolved.

GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 14 Feb 2026, 09:11 PM

Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.

Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.
Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.
Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.
Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.
The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.

💡 Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.

GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore

🟢 POSITIVE ⭐ 8/10

M&A 📅 05 Feb 2026, 05:45 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.

Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)
Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)
Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 months
Strategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolio
Target entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015

💡 Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.

GKSL Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY2025-26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Jan 2026, 09:22 AM

Gujarat Kidney And Super Speciality Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by MUFG Intime India Private Limited, confirms that all dematerialization requests for the quarter ended December 31, 2025, were processed within prescribed timelines. It further verifies that physical certificates were mutilated and cancelled after the name of the depositories was substituted in the register of members. This is a standard administrative filing to ensure the integrity of electronic shareholding records.

Compliance certificate submitted for the third quarter ended December 31, 2025.
Confirmation provided by Registrar and Share Transfer Agent (RTA), MUFG Intime India Private Limited.
Securities received for dematerialization were processed and listed on respective stock exchanges.
Physical security certificates were mutilated and cancelled as per SEBI guidelines.

💡 No action is required from investors as this is a routine regulatory disclosure confirming the company's compliance with share dematerialization procedures.

GKSL to Acquire 49% Stake in Harmony Medicare for ₹10.78 Cr and Ashwini Medical for ₹14 Cr

🟢 POSITIVE ⭐ 8/10

M&A 📅 06 Jan 2026, 07:02 PM

Gujarat Kidney And Super Speciality Limited (GKSL) is consolidating its healthcare portfolio by acquiring the remaining 49% of Harmony Medicare for ₹10.78 Crores, bringing its ownership to 100%. The company is also completing the acquisition of Ashwini Medical Centre for a total of ₹14 Crores, utilizing ₹12.40 Crores from its IPO proceeds for the final payment. Harmony Medicare has shown strong revenue growth, reaching ₹42.29 Crores in FY25 compared to ₹27.70 Crores in FY23. These moves are expected to be finalized within two months and aim to strengthen GKSL's market position in Gujarat.

Acquisition of 49% stake in Harmony Medicare for ₹10.78 Crores to achieve 100% ownership
Harmony Medicare's revenue increased by 52.6% over two years, reaching ₹42.29 Crores in FY25
Approval of ₹12.40 Crores payment from IPO funds for the ₹14 Crores acquisition of Ashwini Medical Centre
Ashwini Medical Centre, a partnership firm, reported a turnover of ₹4.51 Crores for FY25
Both acquisitions are targeted for completion within a two-month timeframe

💡 Investors should view these acquisitions as a positive step toward scale and consolidation of high-growth subsidiaries. Monitor the integration of these entities and their impact on consolidated margins in the upcoming quarterly results.

GKSL to Acquire 100% Stake in Parekhs Hospital for Rs 77 Crore

🟢 POSITIVE ⭐ 9/10

M&A 📅 02 Jan 2026, 11:14 AM

Gujarat Kidney And Super Speciality Limited (GKSL) has announced the 100% acquisition of Parekhs Hospital Private Limited for a cash consideration of Rs 77 crore. Parekhs Hospital is an Ahmedabad-based healthcare provider with a steady turnover, reporting Rs 25.67 crore in FY 2024-25. The acquisition is intended to strengthen GKSL's presence in the healthcare sector and diversify its business portfolio. The transaction is expected to be completed within approximately two months, making Parekhs Hospital a wholly-owned subsidiary.

Acquisition of 100% equity stake (2,55,000 shares) in Parekhs Hospital Private Limited for Rs 77 crore.
Target company reported consistent annual turnover: Rs 25.67 Cr (FY25), Rs 26.36 Cr (FY24), and Rs 24.08 Cr (FY23).
The deal is a pure cash consideration and is expected to close within 2 months.
Parekhs Hospital has been operational since 2006 and is located in Ahmedabad, Gujarat.

💡 Investors should view this as a significant inorganic growth move, though they should monitor how GKSL funds the Rs 77 crore acquisition and its impact on future debt-to-equity levels.

GKSL Announces Trading Window Closure from January 1, 2026 for Q3 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 30 Dec 2025, 08:51 PM

Gujarat Kidney And Super Speciality Limited (GKSL) has announced the closure of its trading window for all designated persons starting January 1, 2026. This regulatory step is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of unaudited financial results for the quarter ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are officially announced. This is a standard procedure for listed companies to ensure transparency and prevent insider trading before earnings releases.

Trading window for dealing in company securities will be closed starting January 1, 2026.
The closure is related to the upcoming approval of unaudited financial results for the quarter ending December 2025.
Restriction applies to all Designated Persons of the company as per SEBI guidelines.
The window will reopen 48 hours after the declaration of the quarterly financial results.

💡 No immediate action is required as this is a routine regulatory filing. Investors should watch for the announcement of the specific board meeting date for Q3 earnings.

View All GKSL Announcements on Live Market Tracking →

💰 Financial Performance

Financial analysis data not yet available for this company.

⚙️ Operational Drivers

Operational analysis data not yet available for this company.

📈 Strategic Growth

Growth Strategy

The company aims to achieve growth through its positioning as a super-speciality hospital, specifically focusing on kidney care. The strategy involves maintaining NABH accreditation standards to attract patients and potentially expanding service offerings within its Vadodara facility to increase patient throughput and revenue per bed.

Products & Services

Super-speciality healthcare services, nephrology treatments, kidney-related surgeries, and general hospital care services.

Brand Portfolio

Gujarat Kidney and Super Speciality Hospital

Strategic Alliances

The company maintains a relationship with MUFG Intime India Private Limited (formerly Link Intime India Private Limited) for share registry and transfer services.

🌍 External Factors

Industry Trends

The healthcare industry is trending toward specialized care and accreditation-driven quality. GKSL is positioned as an NABH-accredited hospital, which is critical for empanelment with insurance providers and corporate clients, potentially increasing patient volume as the demand for organized healthcare grows in Gujarat.

Competitive Moat

The company's moat is built on its specialized focus on kidney care and its NABH accreditation. This provides a competitive advantage in the Vadodara region by establishing trust and quality benchmarks that are difficult for smaller, unorganized clinics to replicate, ensuring a steady flow of specialized cases.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by healthcare-specific regulations including the Clinical Establishments Act and Bio-Medical Waste Management Rules. Compliance with NABH (National Accreditation Board for Hospitals & Healthcare Providers) standards is maintained to ensure operational quality and safety.

⚠️ Risk Analysis

Geographic Concentration Risk

The company has 100% geographic concentration in Vadodara, Gujarat. This makes the business highly vulnerable to local economic shifts, regional competition, and state-specific healthcare policy changes which could impact patient footfall and revenue.